Biowaiver for Lower Strength [Regulatives / Guidelines]

posted by wienui  – Germany/Oman, 2020-11-24 11:42 (1183 d 14:40 ago) – Posting: # 22081
Views: 1,650

Hi Vandee & Ohlbe,

As Ohlbe said, according to EMA for an additional strength biowaiver, the Amount of API(s) must be < 5% of tablet (capsule) core weight for both strengths, the BE strength and the biowaiver one.
Moreover, the Amounts of excipients are the same per strength or Only the amount of a filler is changed to account for changes in API weight.

The FDA doesn't consider this 5% rule and the requirements for an additional strength biowaiver are as following:Both EMA & FDA are asking for the Similarity of dissolution characteristics of the biowaiver strength to the strength for which bioequivalence has been demonstrated in vivo.

I hope this could help.


Complete thread:

UA Flag
 Admin contact
22,899 posts in 4,806 threads, 1,651 registered users;
21 visitors (0 registered, 21 guests [including 9 identified bots]).
Forum time: 02:23 CET (Europe/Vienna)

Statistics is, or should be, about scientific investigation
and how to do it better, but many statisticians believe
it is a branch of mathematics.    George E.P. Box

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz